Hydroxychloroquine use and progression or prognosis of COVID-19: a systematic review and meta-analysis
- PDF / 994,077 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 47 Downloads / 157 Views
ORIGINAL ARTICLE
Hydroxychloroquine use and progression or prognosis of COVID-19: a systematic review and meta-analysis Yanxiang Zang 1 & Xuejie Han 1 & Meijiao He 1 & Jing Shi 1 & Yue Li 1 Received: 22 June 2020 / Accepted: 10 August 2020 # Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract Hydroxychloroquine (HCQ) has been implicated in antiviral activity in vitro against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, there is still controversy about whether HCQ should be used for coronavirus disease 2019 (COVID-19) patients due to the conflicting results in different clinical trials. To systematically assess the benefits and harms of HCQ for the treatment of COVID-19. Data sources were systematically searched from Pubmed, Biorxiv, ChiCTR, Clinicalrials. gov, and the Cochrane library of RCTs for studies published from inception to June 1, 2020, to obtain any possible inclusion. This meta-analysis of inclusion criteria was directed on the basis of the Preferred Reporting Items for Systematic Review and Meta-analysis Protocols (PRISMA-P). Pooled studies by the title and abstract were screened and removed in the light of metaanalysis by two reviewers. Seven studies involving 851 participants with COVID-19 were eligible for analysis. There was no significant difference in RT-PCR negative conversion between HCQ group and standard treatment (ST) group (RR = 1.11, 95% CI = 0.77–1.59, P = 0.591). The rate of exacerbated pneumonia on chest CT in HCQ group was lower than that in ST group (RR = 0.44, 95% CI = 0.20–0.94, P = 0.035). There was no statistical difference in progressed illness between the HCQ group and the ST group (RR = 0.66, 95% CI = 0.18–2.43, P = 0.530). Death (RR = 1.92, 95% CI = 1.26–2.93, P = 0.003) was distinctly different in HCQ group compared with ST group in the treatment of COVID-19. Our meta-analysis demonstrated that there was no robust evidence to support prescribing HCQ as a treatment for COVID-19. Keywords Hydroxychloroquine . COVID-19 . Meta-analysis
Introduction Since December 2019, an outbreak of pneumonia caused by SARS-CoV-2 in Wuhan has spread rapidly throughout China and even around the world. On February 11, 2020, the disease caused by SARS-CoV-2 was officially named as coronavirus disease (COVID-19) by the WHO. In the past few months, there have been more than 7 million confirmed cases and 406 thousand deaths all over the world, posing unprecedented challenges to healthcare systems and amounting to a huge
Yanxiang Zang, Xuejie Han, and Meijiao He were co-first authors in this work. * Yue Li [email protected]; [email protected] 1
Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, 23 Youzheng Street, Nangang District, Harbin, Heilongjiang, People’s Republic of China
economic burden worldwide. However, there are no vaccines or specific antivirals available for SARS-CoV-2 infection. Hydroxychloroquine (HCQ), employed initially for the treatment of malaria, has rapidly gained worldwide attention for its in vi
Data Loading...
